LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to shrink tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to other treatments. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain tumor biomarkers can predi…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New combo therapy before surgery may boost cancer fight in head and neck patients
Disease control Recruiting nowThis study is for people with head and neck cancer that has come back or not gone away. It tests if adding chemotherapy or a chemo-immunotherapy combination before standard salvage surgery can improve outcomes. About 180 participants will receive either chemo or chemo-immunothera…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New combo attack on stubborn head and neck cancers enters human testing
Disease control Recruiting nowThis early-phase trial is for people with head and neck cancer that has persisted or returned after prior treatment. It combines an immunotherapy drug (pembrolizumab) with radiation therapy before and during surgery to see if this approach is safe and can kill more cancer cells. …
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New combo attack on head and neck cancer shows promise in early trial
Disease control Recruiting nowThis early-phase study tests whether combining a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has come back or spread. About 24 adults with limited metastatic disease…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 22, 2026 14:02 UTC